中国神经再生研究(英文版) ›› 2026, Vol. 21 ›› Issue (2): 661-662.doi: 10.4103/NRR.NRR-D-24-01195

• 观点:神经损伤修复保护与再生 • 上一篇    下一篇

小胶质细胞和巨噬细胞的多唾液酸- siglec免疫检查点:治疗干预的前景

  

  • 出版日期:2026-02-15 发布日期:2025-05-23

Polysialic acid-Siglec immune checkpoints of microglia and macrophages: Perspectives for therapeutic intervention

Hauke Thiesler, Herbert Hildebrandt*   

  1. Institute of Clinical Biochemistry, Hannover Medical School and Center for Systems Neuroscience Hannover, Hannover, Germany
  • Online:2026-02-15 Published:2025-05-23
  • Contact: Herbert Hildebrandt, PhD, Hildebrandt.herbert@mh-hannover.de.
  • Supported by:
    We apologize to all authors for papers omitted due to space limitations. Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), project numbers 324633948 and 409784463 (DFG grants Hi 678/9-3 and Hi 678/10- 2, FOR2953) to HH, Bundesministerium für Bildung und Forschung – BMBF, project number 16LW0463K to HT. HT and HH have a patent on “Polysialic acid and derivatives thereof, pharmaceutical composition and method of producing polysialic acid,” WO2020025653A3, issued.

摘要: https://orcid.org/0000-0002-1044-0881 (Herbert Hildebrandt)

Abstract: Microglia are the resident macrophages of the central nervous system. They act as the first line of defense against pathogens and play essential roles in neuroinflammation and tissue repair after brain insult or in neurodegenerative and demyelinating diseases (Borst et al., 2021). Together with infiltrating monocytederived macrophages, microglia also play a critical role for brain tumor development, since immunosuppressive interactions between tumor cells and tumor-associated microglia and macrophages (TAM) are linked to malignant progression. This mechanism is of particular relevance in glioblastoma (GB), the deadliest form of brain cancer with a median overall survival of less than 15 months (Khan et al., 2023). Therefore, targeting microglia and macrophage activation is a promising strategy for therapeutic interference in brain disease.